"My personal goal throughout my career has been to bring important new drugs and innovations to patients, especially for those with serious mental illness, with the aim to make a meaningful difference in the lives of these patients."

Robert McQuade PhD

Independent Director

Senior biopharma executive and Corporate Strategic Advisor for Otsuka America Inc

Bob has more than 35 years of experience in the discovery, development, and marketing of drugs for the treatment of mental illness and kidney diseases. Prior to his retirement from his position as EVP and Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc, Bob was responsible for coordinating the development strategy for Otsuka’s compounds across their life cycles. He is also Chairman of the Management Committee of the MSRD, a limited liability company funded by the Otsuka US pharmaceutical business, which has the purpose to search for, identify and fund innovative early-stage research and development programs that have the potential to build the future portfolio of Otsuka products.

Bob began his career as a research scientist in central nervous system (CNS) drug discovery at Schering-Plough.  Subsequently, Bob held leadership positions at Bristol-Myers Squibb (BMS) in Medical Affairs.

He currently serves on the board of directors of Otsuka America Pharmaceutical, Inc., Astex Pharmaceutical, Inc., Astex Pharmaceutical, Ltd., Avanir Pharmaceuticals, Visterra, Inc.,
Otsuka Pharmaceutical Development & Commercialization, Inc., Medical University of South Carolina Foundation for Research and Development, The Technology Accelerator Co., and Clinical Biotechnology Research Institute.

"My personal goal throughout my career has been to bring important new drugs and innovations to patients, especially for those with serious mental illness, with the aim to make a meaningful difference in the lives of these patients."
Back to Our Team